BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 16790293)

  • 1. Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer.
    Sovak MA; Lutzker S; Zheng L; Guensch L; Joyce M; Schwartz S; Wu Y; Aisner J
    Lung Cancer; 2006 Aug; 53(2):177-81. PubMed ID: 16790293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
    Argiris A; Liptay M; LaCombe M; Marymont M; Kies MS; Sundaresan S; Masters G
    Lung Cancer; 2004 Aug; 45(2):243-53. PubMed ID: 15246197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel.
    Edelman MJ; Gandara DR; Lau DH; Lara P; Lauder IJ; Tracy D
    Cancer; 2001 Jul; 92(1):146-52. PubMed ID: 11443620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.
    Soetekouw PM; Timmer-Bonte JN; van der Drift MA; van Leeuwen F; Wagenaar M; van Die L; Bussink J; Tjan-Heijnen VC
    Int J Clin Oncol; 2013 Dec; 18(6):988-96. PubMed ID: 23011101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
    Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
    Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.
    Zhang J; Gay HA; Russo S; Parent T; Aljumaily R; Walker PR
    Lung Cancer; 2014 Jan; 83(1):67-72. PubMed ID: 24246506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
    Hirsh V; Soulieres D; Duclos M; Faria S; Del Vecchio P; Ofiara L; Ayoub JP; Charpentier D; Gruber J; Portelance L; Souhami L
    J Thorac Oncol; 2007 Oct; 2(10):927-32. PubMed ID: 17909355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
    Hainsworth JD; Burris HA; Erland JB; Morrissey LH; Meluch AA; Kalman LA; Hon JK; Scullin DC; Smith SW; Greco FA
    Cancer; 1999 Mar; 85(6):1269-76. PubMed ID: 10189131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).
    Favaretto A; Ceresoli GL; Paccagnella A; Barbieri F; Bearz A; Ghiotto C; Oniga F; Schiavon S; Frustaci S; Villa E
    Ann Oncol; 2000 Nov; 11(11):1421-6. PubMed ID: 11142482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
    Paccagnella A; Oniga F; Bearz A; Favaretto A; Clerici M; Barbieri F; Riccardi A; Chella A; Tirelli U; Ceresoli G; Tumolo S; Ridolfi R; Biason R; Nicoletto MO; Belloni P; Veglia F; Ghi MG
    J Clin Oncol; 2006 Feb; 24(4):681-7. PubMed ID: 16446341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.
    Chen YM; Perng RP; Lee YC; Shih JF; Lee CS; Tsai CM; Whang-Peng J
    Ann Oncol; 2002 Jan; 13(1):108-15. PubMed ID: 11863090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
    Masters GA; Argiris AE; Hahn EA; Beck JT; Rausch PG; Ye Z; Monberg MJ; Bloss LP; Curiel RE; Obasaju CK
    J Thorac Oncol; 2006 Jan; 1(1):19-24. PubMed ID: 17409822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
    Saito H; Nakagawa K; Takeda K; Iwamoto Y; Ando M; Maeda M; Katakami N; Nakano T; Kurata T; Fukuoka M
    Am J Clin Oncol; 2012 Feb; 35(1):58-63. PubMed ID: 21293243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer.
    Lorusso V; Crucitta E; Panza N; Silvestris N; Guida M; Carpagnano F; Mancarella S; Sambiasi D; De Lena M
    Ann Oncol; 2002 Dec; 13(12):1862-7. PubMed ID: 12453853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
    Banna GL; Lipari H; Nicolosi M; Basile A; Fraggetta F; Vaglica M; Marletta F; Urso OE; Ippolito M; Terminella A; Saita S
    Med Oncol; 2013 Jun; 30(2):533. PubMed ID: 23512427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
    Treat J; Edelman MJ; Belani CP; Socinski MA; Monberg MJ; Chen R; Obasaju CK;
    Lung Cancer; 2010 Dec; 70(3):340-6. PubMed ID: 20347506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.
    Langer C; Li S; Schiller J; Tester W; Rapoport BL; Johnson DH;
    J Clin Oncol; 2007 Feb; 25(4):418-23. PubMed ID: 17264337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer.
    Gillenwater HH; Stinchcombe TE; Qaqish BF; Tyann M; Hensing TA; Socinski MA
    Lung Cancer; 2005 Mar; 47(3):413-9. PubMed ID: 15713525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer.
    Minami S; Kijima T; Shiroyama T; Okafuji K; Hirashima T; Uchida J; Imamura F; Osaki T; Nakatani T; Ogata Y; Yamamoto S; Namba Y; Otsuka T; Tachibana I; Komuta K; Kawase I
    BMC Res Notes; 2013 Jan; 6():3. PubMed ID: 23281805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.